Associations Between Availability and Coverage of HIV-prevention Measures and Subsequent Incidence of Diagnosed HIV Infection Among Injection Drug Users

Overview

Journal Am J Public Health

Specialty Public Health

Date 2009 Apr 18

PMID 19372511

Citations 18

Authors

Lucas Wiessing

Giedrius Likatavicius

Danica Klempova

Dagmar Hedrich

Anthony Nardone

Paul Griffiths

Affiliations

Soon will be listed here.

Abstract

HIV-prevention measures specific to injection drug users (IDUs), such as opioid substitution treatment and needle-and-syringe programs, are not provided in many countries where injection drug use is endemic. We describe the incidence of diagnosed HIV infection in IDUs and the availability and coverage of opioid substitution and needle-and-syringe programs in the European Union and 5 middle- and high-income countries. Countries with greater provision of both prevention measures in 2000 to 2004 had lower incidence of diagnosed HIV infection in 2005 and 2006.

Citing Articles

Impact of COVID-19 & Response Measures on HIV-HCV Prevention Services and Social Determinants in People Who Inject Drugs in 13 Sites with Recent HIV Outbreaks in Europe, North America and Israel.

Wiessing L, Sypsa V, Abagiu A, Arble A, Berndt N, Bosch A AIDS Behav. 2022; 27(4):1140-1153.

PMID: 36367613 PMC: 9651099. DOI: 10.1007/s10461-022-03851-x.

Understanding the crisis in harm reduction funding in Central and Eastern Europe.

Miovsky M, Miklikova S, Mravcik V, Grund J, cernikova T Harm Reduct J. 2020; 17(1):83.

PMID: 33092597 PMC: 7579931. DOI: 10.1186/s12954-020-00428-6.

Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs.

Platt L, Minozzi S, Reed J, Vickerman P, Hagan H, French C Cochrane Database Syst Rev. 2017; 9:CD012021.

PMID: 28922449 PMC: 5621373. DOI: 10.1002/14651858.CD012021.pub2.

Needle and syringe programmes and opioid substitution therapy for preventing HCV transmission among people who inject drugs: findings from a Cochrane Review and meta-analysis.

Platt L, Minozzi S, Reed J, Vickerman P, Hagan H, French C Addiction. 2017; 113(3):545-563.

PMID: 28891267 PMC: 5836947. DOI: 10.1111/add.14012.

Monitoring quality and coverage of harm reduction services for people who use drugs: a consensus study.

Wiessing L, Ferri M, Belackova V, Carrieri P, Friedman S, Folch C Harm Reduct J. 2017; 14(1):19.

PMID: 28431584 PMC: 5401609. DOI: 10.1186/s12954-017-0141-6.

References

Wiessing L, Nardone A . Ongoing HIV and viral hepatitis infections in IDUs across the EU, 2001-2005. Euro Surveill. 2007; 11(11):E061123.2. DOI: 10.2807/esw.11.47.03084-en. View

Sarang A, Stuikyte R, Bykov R . Implementation of harm reduction in Central and Eastern Europe and Central Asia. Int J Drug Policy. 2007; 18(2):129-35. DOI: 10.1016/j.drugpo.2006.11.007. View

Hankins C . Syringe exchange in Canada: good but not enough to stem the HIV tide. Subst Use Misuse. 1998; 33(5):1129-46. DOI: 10.3109/10826089809062211. View

Des Jarlais D, Marmor M, Paone D, Titus S, Shi Q, Perlis T . HIV incidence among injecting drug users in New York City syringe-exchange programmes. Lancet. 1996; 348(9033):987-91. DOI: 10.1016/s0140-6736(96)02536-6. View

Hammett T, Wu Z, Duc T, Stephens D, Sullivan S, Liu W . 'Social evils' and harm reduction: the evolving policy environment for human immunodeficiency virus prevention among injection drug users in China and Vietnam. Addiction. 2007; 103(1):137-45. DOI: 10.1111/j.1360-0443.2007.02053.x. View

van den Berg C, Smit C, van Brussel G, Coutinho R, Prins M . Full participation in harm reduction programmes is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: evidence from the Amsterdam Cohort Studies among drug users. Addiction. 2007; 102(9):1454-62. PMC: 2040242. DOI: 10.1111/j.1360-0443.2007.01912.x. View

Sendziuk P . Harm reduction and HIV-prevention among injecting drug users in Australia: an international comparison. Can Bull Med Hist. 2007; 24(1):113-29. DOI: 10.3138/cbmh.24.1.113. View

. Role of the National Centre in HIV Epidemiology and Clinical Research in surveillance for HIV/ AIDS, viral hepatitis and sexually transmissible infections in Australia. Commun Dis Intell Q Rep. 2004; 28(2):273-6. View

Barnett P, Hui S . The cost-effectiveness of methadone maintenance. Mt Sinai J Med. 2000; 67(5-6):365-74. View

10.

Aceijas C, Hickman M, Donoghoe M, Burrows D, Stuikyte R . Access and coverage of needle and syringe programmes (NSP) in Central and Eastern Europe and Central Asia. Addiction. 2007; 102(8):1244-50. DOI: 10.1111/j.1360-0443.2007.01848.x. View

11.

Popova S, Rehm J, Fischer B . An overview of illegal opioid use and health services utilization in Canada. Public Health. 2006; 120(4):320-8. DOI: 10.1016/j.puhe.2005.09.010. View

12.

Loxley . Doing the possible: harm reduction, injecting drug use and blood borne viral infections in Australia. Int J Drug Policy. 2000; 11(6):407-416. DOI: 10.1016/s0955-3959(00)00067-0. View

13.

Mathers B, Degenhardt L, Phillips B, Wiessing L, Hickman M, Strathdee S . Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. Lancet. 2008; 372(9651):1733-45. DOI: 10.1016/S0140-6736(08)61311-2. View

14.

Sarang A, Rhodes T, Platt L . Access to syringes in three Russian cities: implications for syringe distribution and coverage. Int J Drug Policy. 2008; 19 Suppl 1:S25-36. DOI: 10.1016/j.drugpo.2007.11.008. View

15.

Razali K, Thein H, Bell J, Cooper-Stanbury M, Dolan K, Dore G . Modelling the hepatitis C virus epidemic in Australia. Drug Alcohol Depend. 2007; 91(2-3):228-35. DOI: 10.1016/j.drugalcdep.2007.05.026. View

16.

Tempalski B, Cooper H, Friedman S, Des Jarlais D, Brady J, Gostnell K . Correlates of syringe coverage for heroin injection in 35 large metropolitan areas in the US in which heroin is the dominant injected drug. Int J Drug Policy. 2008; 19 Suppl 1:S47-58. PMC: 2706511. DOI: 10.1016/j.drugpo.2007.11.011. View

17.

Burrows D . Injecting equipment provision in Australia: the state of play. Subst Use Misuse. 1998; 33(5):1113-27. DOI: 10.3109/10826089809062210. View

18.

Bruce R, Dvoryak S, Sylla L, Altice F . HIV treatment access and scale-up for delivery of opiate substitution therapy with buprenorphine for IDUs in Ukraine--programme description and policy implications. Int J Drug Policy. 2007; 18(4):326-8. PMC: 2084072. DOI: 10.1016/j.drugpo.2006.12.011. View

19.

Ball A, Rana S, Dehne K . HIV prevention among injecting drug users: responses in developing and transitional countries. Public Health Rep. 1998; 113 Suppl 1:170-81. PMC: 1307739. View